vs
Side-by-side financial comparison of AlTi Global, Inc. (ALTI) and MESA LABORATORIES INC (MLAB). Click either name above to swap in a different company.
AlTi Global, Inc. is the larger business by last-quarter revenue ($86.6M vs $65.1M, roughly 1.3× MESA LABORATORIES INC). MESA LABORATORIES INC runs the higher net margin — 5.6% vs -15.1%, a 20.7% gap on every dollar of revenue. On growth, AlTi Global, Inc. posted the faster year-over-year revenue change (87.0% vs 3.6%). MESA LABORATORIES INC produced more free cash flow last quarter ($18.0M vs $-52.2M). Over the past eight quarters, AlTi Global, Inc.'s revenue compounded faster (30.6% CAGR vs 5.1%).
Cristal Global is the world's second-largest producer of titanium dioxide and a leading producer of titanium chemicals. It was formed when The National Titanium Dioxide Company Ltd. combined with Millennium Chemicals. The headquarters are in Jeddah, Saudi Arabia. It is a significant shareholder in Bemax, the world’s 5th largest TiO2 feedstock producer.
Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.
ALTI vs MLAB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.6M | $65.1M |
| Net Profit | $-13.1M | $3.6M |
| Gross Margin | — | 64.2% |
| Operating Margin | -2.1% | 12.2% |
| Net Margin | -15.1% | 5.6% |
| Revenue YoY | 87.0% | 3.6% |
| Net Profit YoY | 75.6% | 316.6% |
| EPS (diluted) | — | $0.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.6M | $65.1M | ||
| Q3 25 | $57.2M | $60.7M | ||
| Q2 25 | $53.1M | $59.5M | ||
| Q1 25 | $58.0M | $62.1M | ||
| Q4 24 | $46.3M | $62.8M | ||
| Q3 24 | $51.8M | $57.8M | ||
| Q2 24 | $49.5M | $58.2M | ||
| Q1 24 | $50.8M | $58.9M |
| Q4 25 | $-13.1M | $3.6M | ||
| Q3 25 | $-84.1M | $2.5M | ||
| Q2 25 | $-24.4M | $4.7M | ||
| Q1 25 | $1.9M | $-7.1M | ||
| Q4 24 | $-53.8M | $-1.7M | ||
| Q3 24 | $-72.5M | $3.4M | ||
| Q2 24 | $-6.4M | $3.4M | ||
| Q1 24 | $29.7M | $-254.6M |
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
| Q4 25 | -2.1% | 12.2% | ||
| Q3 25 | -49.8% | 7.8% | ||
| Q2 25 | -56.7% | 5.1% | ||
| Q1 25 | -23.3% | 2.4% | ||
| Q4 24 | -42.7% | 9.2% | ||
| Q3 24 | -18.4% | 6.1% | ||
| Q2 24 | -30.2% | 9.6% | ||
| Q1 24 | -28.9% | -460.6% |
| Q4 25 | -15.1% | 5.6% | ||
| Q3 25 | -147.0% | 4.1% | ||
| Q2 25 | -45.9% | 8.0% | ||
| Q1 25 | 3.3% | -11.4% | ||
| Q4 24 | -116.1% | -2.7% | ||
| Q3 24 | -140.0% | 5.9% | ||
| Q2 24 | -12.9% | 5.8% | ||
| Q1 24 | 58.4% | -432.2% |
| Q4 25 | — | $0.65 | ||
| Q3 25 | — | $0.45 | ||
| Q2 25 | $-0.33 | $0.85 | ||
| Q1 25 | $-0.04 | $-1.30 | ||
| Q4 24 | $-0.71 | $-0.31 | ||
| Q3 24 | $-0.88 | $0.63 | ||
| Q2 24 | $-0.18 | $0.62 | ||
| Q1 24 | $0.18 | $-47.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.2M | $29.0M |
| Total DebtLower is stronger | $883.0K | $68.4M |
| Stockholders' EquityBook value | $600.1M | $186.7M |
| Total Assets | $1.2B | $434.8M |
| Debt / EquityLower = less leverage | 0.00× | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $41.2M | $29.0M | ||
| Q3 25 | $35.8M | $20.4M | ||
| Q2 25 | $42.4M | $21.3M | ||
| Q1 25 | $52.8M | $27.3M | ||
| Q4 24 | $64.4M | $27.3M | ||
| Q3 24 | $220.6M | $24.3M | ||
| Q2 24 | $60.0M | $28.5M | ||
| Q1 24 | $134.2M | $28.2M |
| Q4 25 | $883.0K | $68.4M | ||
| Q3 25 | $586.0K | $69.4M | ||
| Q2 25 | $673.0K | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | $0 | $72.2M | ||
| Q3 24 | $128.4M | $73.1M | ||
| Q2 24 | $164.0M | $74.1M | ||
| Q1 24 | $183.7M | — |
| Q4 25 | $600.1M | $186.7M | ||
| Q3 25 | $607.2M | $178.5M | ||
| Q2 25 | $685.4M | $172.5M | ||
| Q1 25 | $665.2M | $159.8M | ||
| Q4 24 | $658.4M | $155.2M | ||
| Q3 24 | $707.0M | $161.5M | ||
| Q2 24 | $540.2M | $150.7M | ||
| Q1 24 | $510.9M | $145.4M |
| Q4 25 | $1.2B | $434.8M | ||
| Q3 25 | $1.2B | $430.4M | ||
| Q2 25 | $1.2B | $435.7M | ||
| Q1 25 | $1.2B | $433.3M | ||
| Q4 24 | $1.3B | $433.3M | ||
| Q3 24 | $1.4B | $454.1M | ||
| Q2 24 | $1.3B | $440.4M | ||
| Q1 24 | $1.3B | $446.8M |
| Q4 25 | 0.00× | 0.37× | ||
| Q3 25 | 0.00× | 0.39× | ||
| Q2 25 | 0.00× | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | 0.00× | 0.47× | ||
| Q3 24 | 0.18× | 0.45× | ||
| Q2 24 | 0.30× | 0.49× | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-51.4M | $18.8M |
| Free Cash FlowOCF − Capex | $-52.2M | $18.0M |
| FCF MarginFCF / Revenue | -60.3% | 27.7% |
| Capex IntensityCapex / Revenue | 0.9% | 1.1% |
| Cash ConversionOCF / Net Profit | — | 5.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | $37.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-51.4M | $18.8M | ||
| Q3 25 | $-53.5M | $8.2M | ||
| Q2 25 | $-19.9M | $1.9M | ||
| Q1 25 | $-30.2M | $12.7M | ||
| Q4 24 | $-50.7M | $18.1M | ||
| Q3 24 | $-4.9M | $5.3M | ||
| Q2 24 | $-30.2M | $10.7M | ||
| Q1 24 | $-15.5M | $12.9M |
| Q4 25 | $-52.2M | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | $-20.0M | $884.0K | ||
| Q1 25 | $-31.0M | $11.9M | ||
| Q4 24 | $-58.2M | $17.3M | ||
| Q3 24 | $-9.4M | $3.5M | ||
| Q2 24 | $-31.2M | $9.9M | ||
| Q1 24 | $-15.7M | $12.3M |
| Q4 25 | -60.3% | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | -37.6% | 1.5% | ||
| Q1 25 | -53.4% | 19.2% | ||
| Q4 24 | -125.7% | 27.6% | ||
| Q3 24 | -18.2% | 6.0% | ||
| Q2 24 | -63.2% | 16.9% | ||
| Q1 24 | -30.9% | 21.0% |
| Q4 25 | 0.9% | 1.1% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 1.3% | 1.2% | ||
| Q4 24 | 16.3% | 1.3% | ||
| Q3 24 | 8.7% | 3.1% | ||
| Q2 24 | 2.2% | 1.5% | ||
| Q1 24 | 0.4% | 0.9% |
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | -15.80× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | -0.52× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALTI
| Management Advisory Fees | $51.1M | 59% |
| Other | $32.7M | 38% |
| Distributions From Investments | $2.9M | 3% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
